These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34413629)

  • 1. HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma.
    Xu Y; Huang Z; Yu X; Li Z; Zheng L; Xu J
    Biologics; 2021; 15():329-341. PubMed ID: 34413629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma.
    Li W; You J; Xue H; Liu Y; Chen J; Zheng X; Chen L; Wu C
    Cancer Immunol Immunother; 2024 Aug; 73(10):207. PubMed ID: 39105870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
    Luo M; Lin Y; Liang R; Li Y; Ge L
    J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
    Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
    Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
    Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Front Immunol; 2022; 13():831101. PubMed ID: 35371079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
    Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
    Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
    Liao X; Zhang D
    Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
    Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
    Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 immune-regulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
    Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
    Front Immunol; 2022; 13():902167. PubMed ID: 36003385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
    Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
    Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
    Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
    Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
    Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
    Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
    Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
    Zhang X; Qin Y; Chen X; Xiong M; Shu S
    Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
    [No Abstract]   [Full Text] [Related]  

  • 20. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients.
    Chen L; Zhu D; Feng J; Zhou Y; Wang Q; Feng H; Zhang J; Jiang J
    Cancer Cell Int; 2019; 19():101. PubMed ID: 31015801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.